2022 was marked with some major shocks to the global blockchain industry that encountered another enduring ‘crypto winter’, the collapse of TerraUSD and Luna, and FTX’s fil… Read More
The antibody-drug conjugate (ADC) inotuzumab ozogamicin (Besponsa) combined with low-intensity chemotherapy — with or without blinatumomab (Blincyto) — showed promise in ol… Read More
Central Garden & Pet Company: A Promising Investment Opportunity
The past weeks have seen Central Garden & Pet’s stock (NASDAQ:CENTA) open at $37.20 on Friday, with a 52-week l… Read More